Precision Biosciences Inc announced it raised $88.1 Million in an initial filing from an offering of $110 Million

Company

Location

About

Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical stage gene editing company developing in vivo gene editing with its highly precise and versatile ARCUS genome editing platform. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases designed for gene knock out, as well as highly complex edits for gene insertion and/or gene repair. Precision BioSciences is based in Durham, North Carolina.